UPDATE 2-Orthovita gets FDA OK for new protein processing plant

* To use new facility for processing collagen

* To use collagen in its device to control bleeding

* Shares rise 5 pct
(Adds details, updates share movement)

July 26 (BestGrowthStock) – Orthovita Inc (VITA.O: ) said U.S. health
regulators approved the use of its new facility to process a
type of protein, collagen, which is used in its device to
control bleeding, sending its shares up 5 percent.

The medical device maker said its new collagen processing
facility in Malvern, Pennsylvania will provide it with an
opportunity to develop, manufacture and market additional
collagen-based products.

Orthovita’s U.S. Food and Drug Administration-approved
Vitagel surgical hemostat device combines collagen and
thrombin, a coagulation protein, with the patient’s own plasma
to control bleeding during surgical procedures.

In 2006, Orthovita received FDA approval to market Vitagel
surgical hemostat, and it gained European approval in 2007.

Shares of the company were up 4 percent at $1.94 in morning
trade Monday on Nasdaq. They earlier touched a high of $1.96.

Stock Market Analysis

(Reporting by Anand Basu in Bangalore; Editing by Prem
Udayabhanu and Gopakumar Warrier)

UPDATE 2-Orthovita gets FDA OK for new protein processing plant